Last updated: February 19, 2026
Procarbazine hydrochloride is an alkylating agent primarily used in chemotherapy regimens for Hodgkin's lymphoma. Its supply chain is limited to specialized pharmaceutical manufacturers and chemical intermediaries.
Key Suppliers Overview
| Supplier Name |
Country |
Manufacturing Status |
Notes |
| TCI America |
Japan/USA |
Produces active ingredient |
Known for high-quality APIs; offers bulk procurement |
| Hangzhou Asiastar Pharma |
China |
Contract manufacturing |
Supplies both active substance and finished formulations |
| CPL Biologicals |
India |
Produces active ingredient |
Supplies to domestic and international markets |
| Hanlim Pharmaceutical |
South Korea |
Produces active compound |
Focuses on generic APIs in oncology |
| Toronto Research Chemicals |
Canada |
Chemical supplier |
Provides research-grade procarbazine hydrochloride |
Raw Material and API Production
- Procarbazine hydrochloride synthesis involves multi-step chemical processes, requiring specialized chemical intermediates.
- Manufacturers typically set up licensing agreements or supply contracts with raw material producers.
- Quality standards include compliance with USP, EP, or JP pharmacopeial standards, depending on the market.
Market Access and Distribution
- Limited approved suppliers with licensed manufacturing capabilities.
- Distribution primarily through licensed pharmaceutical wholesalers.
- Regulatory approvals impose strict controls on manufacturing practices, making new suppliers rare.
Regulatory and Patent Status
- Patent Status: The original patent expired decades ago, enabling generic production.
- Regulatory approvals vary by country; suppliers must obtain necessary certifications (e.g., FDA, EMA).
Summary of Major Suppliers
- TCI America has a long history of API production for oncology drugs, including procarbazine hydrochloride.
- Hangzhou Asiastar Pharma and CPL Biologicals serve large markets in Asia with high-volume manufacturing.
- Toronto Research Chemicals supplies research-grade materials, used mainly for scientific research and not clinical applications.
Supply Chain Challenges
- Limited number of high-quality, licensed suppliers.
- Strict regulatory standards increase time-to-market for new suppliers.
- Raw material sourcing can be complex due to chemical synthesis routes.
Conclusion
The global supply of procarbazine hydrochloride depends on a handful of specialized chemical and pharmaceutical companies. The market is consolidated, with top producers based in Japan, China, India, and South Korea, serving both clinical and research markets.
Key Takeaways
- Procarbazine hydrochloride has a limited number of authorized suppliers, primarily in Asia and North America.
- Major suppliers are TCI America, Hangzhou Asiastar Pharma, CPL Biologicals, and Toronto Research Chemicals.
- Product quality, regulatory compliance, and manufacturing capacity dictate market access.
- The patent landscape allows for generic production, but regulatory hurdles limit new entrants.
FAQs
1. Who are the leading manufacturers of procarbazine hydrochloride?
TCI America, Hangzhou Asiastar Pharma, CPL Biologicals, and Toronto Research Chemicals.
2. Can new suppliers enter the market easily?
No. Regulatory requirements and established distribution channels limit market entry.
3. Is procarbazine hydrochloride supplied as a finished drug or just raw material?
Suppliers provide both active pharmaceutical ingredients (APIs) and, in some cases, finished formulations.
4. What quality standards must suppliers meet?
Manufacturers must comply with pharmacopeial standards such as USP, EP, or JP.
5. Are there regional differences in supplier availability?
Yes. Asian suppliers dominate bulk API production, while North American suppliers focus on research-grade materials.
References
[1] U.S. Food and Drug Administration. (2022). Pharmaceutical Quality API Standards.
[2] European Medicines Agency. (2021). Guidelines on API Manufacturing.
[3] Chemical Suppliers and API Producers Directory. (2023). International Chemical Suppliers List.
[4] Canadian Chemical Suppliers Market Report. (2022).
[5] Pharmaceutical Industry Reports 2023.
